全文获取类型
收费全文 | 437606篇 |
免费 | 30843篇 |
国内免费 | 7388篇 |
专业分类
耳鼻咽喉 | 5791篇 |
儿科学 | 8853篇 |
妇产科学 | 10665篇 |
基础医学 | 60090篇 |
口腔科学 | 12794篇 |
临床医学 | 37895篇 |
内科学 | 86536篇 |
皮肤病学 | 9084篇 |
神经病学 | 30402篇 |
特种医学 | 16309篇 |
外国民族医学 | 116篇 |
外科学 | 66854篇 |
综合类 | 20707篇 |
现状与发展 | 17篇 |
一般理论 | 65篇 |
预防医学 | 21480篇 |
眼科学 | 11196篇 |
药学 | 37419篇 |
50篇 | |
中国医学 | 5457篇 |
肿瘤学 | 34057篇 |
出版年
2021年 | 5260篇 |
2020年 | 4072篇 |
2019年 | 4835篇 |
2018年 | 6726篇 |
2017年 | 5404篇 |
2016年 | 5379篇 |
2015年 | 7027篇 |
2014年 | 9309篇 |
2013年 | 10445篇 |
2012年 | 14827篇 |
2011年 | 15517篇 |
2010年 | 9617篇 |
2009年 | 8347篇 |
2008年 | 12630篇 |
2007年 | 13582篇 |
2006年 | 13435篇 |
2005年 | 12647篇 |
2004年 | 10919篇 |
2003年 | 10543篇 |
2002年 | 9880篇 |
2001年 | 29498篇 |
2000年 | 30158篇 |
1999年 | 25079篇 |
1998年 | 6012篇 |
1997年 | 5042篇 |
1996年 | 4407篇 |
1995年 | 4162篇 |
1994年 | 3756篇 |
1993年 | 3219篇 |
1992年 | 16440篇 |
1991年 | 15160篇 |
1990年 | 14466篇 |
1989年 | 14221篇 |
1988年 | 12781篇 |
1987年 | 12230篇 |
1986年 | 11226篇 |
1985年 | 10402篇 |
1984年 | 6959篇 |
1983年 | 5645篇 |
1982年 | 2750篇 |
1979年 | 5493篇 |
1978年 | 3348篇 |
1977年 | 2966篇 |
1975年 | 2640篇 |
1974年 | 3064篇 |
1973年 | 2870篇 |
1972年 | 2828篇 |
1971年 | 2773篇 |
1970年 | 2509篇 |
1969年 | 2544篇 |
排序方式: 共有10000条查询结果,搜索用时 171 毫秒
41.
目的 对生化汤加味促进剖宫产后子宫复旧的有效性与安全性进行系统评价,为其在临床应用提供循证医学证据。方法 检索中国生物医学文献数据库(CBM)、中国知网(CNKI)、万方资源数据库(WanFang)、维普期刊数据库(VIP)、Cochrane Library、PubMed、Web of Science等,检索时限为建库至2020年7月,选择生化汤加味促进剖宫产后子宫复旧的随机对照试验(RCT),采用Cochrane系统评价员手册提供的偏倚风险评估工具进行文献质量评价,应用RevMan5.3软件进行Meta分析。结果 共纳入12篇RCT文献,共计1804例剖宫产产妇;Meta分析结果显示,生化汤加味联合缩宫素组在产后第1、3、5天子宫底高度[MD = -0.75,95%CI(-1.35, -0.15),P < 0.00001;MD = -1.92,95%CI(-3.13, -0.72),P < 0.00001;MD = -1.92,95%CI(-3.79, -0.06),P < 0.00001]低于单用缩宫素组,联合用药组血性恶露时间[MD = -1.52,95%CI(-2.71,-0.34),P < 0.00001]和产后恶露持续时间[MD = -4.47,95%CI(-6.20,-2.75),P < 0.00001]均短于单用缩宫素组。结论 生化汤加味联合缩宫素与单用缩宫素比较,更能促进产后子宫复旧;不良反应少,报道的仅有4例出现轻微腹泻,安全性较高;但由于纳入文献质量较低,上述结论尚需更多的随机对照临床研究加以证实。 相似文献
42.
43.
Yang Luan Yan Zhang Kai Cui Fan Li Baolong Qin Yajun Ruan Kun Tang Hongyang Jiang Hao Li Xiaoyi Yuan Zhuo Liu Xiaming Liu Gan Yu Shengfei Xu Ruibao Chen Huan Yang Xiaolin Guo Xiaoyong Zeng Zhong Chen Zhiqiang Chen Zhiquan Hu Xiaodong Song Zhihua Wang Shaogang Wang Jihong Liu Tao Wang 《Translational andrology and urology》2021,10(1):466
BackgroundTo introduce and determine the value of optimized strategies for the management of urological tube-related emergencies with increased incidence, complexity and operational risk during the global spread of coronavirus disease 2019 (COVID-19).MethodsAll emergent urological patients at Tongji Hospital, Wuhan, during the period of January 23 (the beginning of lockdown in Wuhan) to March 23, 2020, and the corresponding period in 2019 were recruited to form this study’s COVID-19 group and control group, respectively. Tongji Hospital has the most concentrated and strongest Chinese medical teams to treat the largest number of severe COVID-19 patients. Patients in the control group were routinely treated, while patients in the COVID-19 group were managed following the optimized principles and strategies. The case incidence for each type of tube-related emergency was recorded. Baseline characteristics and management outcomes (surgery time, secondary complex operation rate, readmission rate, COVID-19 infection rate) were analyzed and compared across the control and COVID-19 periods.ResultsThe total emergent urological patients during the COVID-19 period was 42, whereas during the control period, it was 124. The incidence of tube-related emergencies increased from 53% to 88% (P<0.001) during the COVID-19 period. In particular, the incidence of nephrostomy tube-related (31% vs. 15%, P=0.027) and single-J stent-related problems (19% vs. 6%, P=0.009) increased significantly. The mean surgery times across the two periods were comparable. The number of secondary complex operations increased from 12 (18%) to 14 (38%) (P=0.028) during the COVID 19-period. The number of 2-week postoperative readmission decreased from 10 (15%) to 1 (3%) (P=0.049). No participants contracted during the COVID-19 period.ConclusionsUrological tube-related emergencies have been found to have a higher incidence and require more complicated and dangerous operations during the COVID-19 pandemic. However, the optimized management strategies introduced in this study are efficient, and safe for both urologists and patients. 相似文献
44.
45.
46.
A novel surgical technique to prevent post-enucleation conjunctival cyst:conjunctival staining with methylthioninium 下载免费PDF全文
Dear Editor,Conjunctival cyst of the orbit acquired from enucleation is an infrequent but serious complication;which can occur in 3%-7%of patients,more commonly after a secondary procedure;.The most common manifestations are the inability to retain the external prosthesis. 相似文献
47.
48.
49.
Mariano E. Menendez Suleiman Y. Sudah Patrick J. Denard 《Seminars in Arthroplasty》2022,32(3):644-649
BackgroundThe growing enthusiasm for the use of reverse shoulder arthroplasty (RSA) in the treatment of primary glenohumeral osteoarthritis (GHOA) with an intact rotator cuff is based on data derived from single-center studies with limited generalizability and follow-up. This study compared patient-reported outcomes (PROs) between RSA and total shoulder arthroplasty (TSA) for the treatment of primary GHOA with up to 5-year follow-up and examined temporal trends in the treatment of GHOA between 2012 and 2021.MethodsA retrospective review was performed on patients with primary GHOA undergoing primary arthroplasty surgery from the Surgical Outcomes System global registry between 2012 and 2021. PROs including the American Shoulder and Elbow Surgeons (ASES) score, Single Assessment Numeric Evaluation (SANE) score, and visual analog scale (VAS) for pain were compared between RSA and TSA at 1, 2, and 5 years postoperatively.ResultsA total of 4451 patients were included, with 2693 (60.5%) undergoing TSA and 1758 (39.5%) undergoing RSA. Both RSA and TSA provided clinically excellent outcomes at 1 year postoperatively (ASES: 80.8 ± 17.9 vs. 85.9 ± 15.2, respectively; SANE: 74.8 ± 24.7 vs. 79.5 ± 22.9; VAS pain: 1.3 ± 2.0 vs. 1.1 ± 1.7; all P < .05) that were maintained at 2 years (ASES: 81.3 ± 19.3 vs. 87.3 ± 14.9; SANE: 74.8 ± 26.2 vs. 79.7 ± 24.7; VAS pain: 1.3 ± 2.1 vs. 1.0 ± 1.6; all P < .05) and 5 years (ASES: 81.7 ± 16.5 vs. 86.9 ± 15.3; SANE: 71.6 ± 28.5 vs. 78.2 ± 25.9; VAS pain: 1.0 ± 1.7 vs. 1.0 ± 1.7; all P < .05), with statistical significance favoring TSA. After controlling for age and sex, there was an adjusted difference of 4.5 units in the ASES score favoring TSA (P = .005) at 5 years postoperatively but no differences in adjusted SANE (P = .745) and VAS pain (P = .332) scores. The use of RSA for GHOA grew considerably over time, from representing only 17% of all replacements performed for GHOA in 2012 to nearly half (47%) in 2021 (P < .001).ConclusionRSA as a treatment for GHOA with an intact rotator cuff seems to yield PROs that are largely clinically equivalent to TSA extending to 5 years postoperatively. The observed statistical significance favoring TSA appears to be of marginal clinical benefit based on established minimal clinically important differences and may be a result of the large sample size. Further research using more granular clinical data and examining differences in range of motion and complications is warranted as it may change the value analysis. 相似文献
50.
Prevention Science - This study aimed to evaluate the effectiveness of the drug and violence resistance educational program (PROERD) on short-term secondary outcomes, such as intentions to use... 相似文献